reports
Prime Medicine Inc: 3 directors
Three Directors at Prime Medicine Inc bought/maiden bought 245,000 shares at between 1.130USD and 1.190USD. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...
- Jonathan Moreland
LIND LINDBLAD EXPEDITIONS HOLDINGS
BXC BLUELINX HOLDINGS
GPMT GRANITE POINT MORTGAGE TRUST INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
BBDC BARINGS BDC INC.
MIDD THE MIDDLEBY CORPORATION
ENR EDGEWELL PERSONAL CARE COMPANY
AVTR AVANTOR
VLA INC.
HQL ARBOR METALS
ONEW TEKLA LIFE SCIENCES INVESTORS
ZIP ONEWATER MARINE
UDMY ZIPRECRUITER
OPAL INC.
PRME UDEMY INC
SDHC OPAL FUELS INC
FIP PRIME MEDICINE INC
EVM SMITH DOUGLAS HOMES CORP
GF FTAI INFRASTRUCTURE INC
FINS EATON VANCE INSD CALIF MUN BD FD
THE NEW GERMANY FUND
INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
Prime Medicine Announces Strategic Restructuring to Focus on Opportuni...
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition -- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff ...
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Rest...
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease -- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- -- Rapid engraftment observed in both neutrophils and platelets -- -- Encouraging safety profile; no serious adv...
- David Nierengarten
- Dennis Pak
- Martin Fan
Prime Medicine Reports First Quarter 2025 Financial Results and Provid...
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates -- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results f...
- David Nierengarten
- Dennis Pak
- Martin Fan
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- David Nierengarten
- Dennis Pak
- Martin Fan
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsi...
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) -- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High levels of editing at the target site in preclinical studies with full restoration of circulating wild-type AAT protein (M-AAT) to normal human range -- -- Expects to file IND and/or CTA in mid-2026 -- CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotech...
Prime Medicine Reports Full Year 2024 Financial Results and Provides B...
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates -- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, t...
- David Nierengarten
- Dennis Pak
- Martin Fan
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conferen...
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, MA. A live audio webcast of the presentation will be available ...
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Confer...
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA. A live audio webcast of the presentation w...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EBAY EBAY INC.
BPMC BLUEPRINT MEDICINES CORP.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
OVID OVID THERAPEUTICS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
YMAB Y-MABS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
BEAM INC.
COGT BEAM THERAPEUTICS
IMNM COGENT BIOSCIENCES INC
VOR IMMUNOME
STX VOR BIOPHARMA
GFS SEAGATE TECHNOLOGY HLDGS PLC
GMTX GLOBALFOUNDRIES INC
ARTV GEMINI THERAPEUTICS INC
PRME ARTIVA BIOTHERAPEUTICS INC
PRIME MEDICINE INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
TSLA TESLA INC
LOW LOWE'S COMPANIES INC.
HD HOME DEPOT INC.
GPC GENUINE PARTS COMPANY
FATE FATE THERAPEUTICS INC
AZO AUTOZONE INC.
AAP ADVANCE AUTO PARTS INC.
ORLY O'REILLY AUTOMOTIVE INC.
OVID OVID THERAPEUTICS
ISR ISORAY
LEGH LEGACY HOUSING CORP
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
RKT ROCKET COMPANIES
TLS TELOS
RMBL RUMBLEON INC
ALIT FOLEY TRASIMENE ACQUISITION CORP
AVTE AEROVATE THERAPEUTICS INC
SOUN SOUNDHOUND AI INC
ARTV ARTIVA BIOTHERAPEUTICS INC
PRME PRIME MEDICINE INC
CAVA CAVA GROUP INC
CART MAPLEBEAR INC.
ANRO ALTO NEUROSCIENCE INC
Prime Medicine Reports Third Quarter 2024 Financial Results and Provid...
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates -- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024 and remains on track to file IND and/or CTA in 1H 2026 -- -- Announced strategic research collaboration and license agreement with Bristol Myers Squibb; received $110 million upfront, with potential for more than $3.5 billion in milestone payments -- -- On track to report initial data from Phase 1/2 clinical trial of P...
- David Nierengarten
- Dennis Pak
- Martin Fan
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Guggenheim's Inaugural Healthcare Innovation Conference: Fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024, at 1:15 p.m. ET in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.